

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT APPLICATION

Group Art Unit 1644
 Examiner: P. Gambel
 Atty. Dkt. P 0275823

1644 \$
1995-30-0232C2

Appln. Title: TREATMENT OF T CELL MEDIATED
 AUTOIMMUNE DISORDERS

RECEIVED

JUN 19 2002

Inventor(s): NOELLE et al.

Appln. No.: 09 | 223,634

Series Code ↑

Serial No. ↑

Filed: December 31, 1998

Hon. Commissioner of Patents
 Washington, D.C. 20231

Sir:

REPLY/AMENDMENT/LETTER

Date: June 12, 2002

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

FEE REQUIREMENTS FOR CLAIMS AS AMENDED

1. Small Entity claim

- A. ☒ NOT made
 B. ☐ Withdrawn
 C. ☐ made herewith
 D. ☐ made previously

For B & C
 See Required
Separate Paper
 (Pat-256)

| Claims remaining after amendment | Highest number previously paid for | Present Extra | Large/Small Entity | Additional Fee | Fee Code Lg/Sm |
|--|------------------------------------|--|--------------------|-----------------------|---|
| 2. Total Effective Claims | 17 | **minus 20 | 0 | x \$18/\$9 = + \$0 | 103/203 |
| 3. Independent Claims | 4 | ***minus 3 | 1 | x \$84/\$42 = + \$84 | 102/202 |
| 4. If amendment enters proper multiple dependent claim(s) into this application for first time (leave blank if this is a reissue application)..... add | | | | + \$280/\$140 = + \$0 | 104/204 |
| 5. Original due Date: June 12, 2002 | | <input type="checkbox"/> NONE | | | |
| 6. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached | | (1 mo) \$110/\$55 = (2 mos) \$400/\$200 = (3 mos) \$920/\$460 = (Usable only for ≤ 2mo.OA --- 4 mos) \$1,440/\$720= (Usable only for 30 day/1mo.OA --- 5 mos) \$1,960/\$980= | + \$0 | | 115/215 116/216 117/217 118/218 128/228 |
| 7. Enter any previous extension fee paid since above original due date and subtract | | | - \$0 | | |
| 8. | | | Extension Fee | + \$0 | |
| 9. If Terminal Disclaimer attached, add Rule 20(d) official fee | | | + \$110/\$55 | + \$0 | 148/248 |
| 10. If IDS attached requires Official Fee under Rule 97 (c), add | | | + \$180 | + \$0 | 126 |
| or if Rule 97(d) Request add | | | + \$180 | | 126 |
| 11. After-Final Request Fee per rules 129(a) and 17(r) | | | + \$740/370 | + \$0 | 146/246 |
| 12. No. of additional inventions for examination per Rule 129(b)..... | | | x \$740/370 ea | + \$0 | 149/249 |
| 13. Request for Continued Examination (RCE) | | | + \$740/370 | + \$0 | 1179/1279 |
| 14. Petition fee for | | | | + \$0 | |
| 15. | | | | TOTAL FEE = | \$84 |

16. *If the entry in this space is less than entry in next space, the "Present Extra" result is "0".

17. **If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.

18. ***If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.

Our Deposit Account No. 03-3975)

(Our Order No. 037003 | 0275823

C#

M#

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown above, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately.


Pillsbury Winthrop LLP
 Intellectual Property Group

By Atty: Robin L. Teskin

Reg. No. 35,030

1600 Tysons Boulevard
 McLean, VA 22102
 Tel: (703) 905-2000


Sig:



Fax: (703) 905-2500
 Tel: (703) 905-2200

Atty/Sec: RLT/AF

NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments



17/F
gnd
6/25/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

Randolph J. NOELLE et al.

Group Art Unit: 1644

Application No. 09/223,634

Examiner: P. GAMBEL

Filed: December 31, 1998

Title: TREATMENT OF T CELL MEDIATED AUTOIMMUNE DISORDERS

RECEIVED

JUN 19 2002

TECH CENTER 1600/2300

* * * * *

REPLY AND AMENDMENT
PURSUANT TO 37 C.F.R. §1.111

Hon. Commissioner of Patents
Washington, D.C. 20231

Sir:

In response to the non-final Office Action mailed on March 12, 2002, kindly amend the above-identified application as follows

IN THE CLAIMS

Kindly cancel claims 1-2, 5-10 and 12 and substitute the following claims.

--13. A method for inhibiting T cell mediated tissue destruction associated with an autoimmune disease other than multiple sclerosis comprising administering an effective amount of a gp39 antagonist selected from the group consisting of soluble CD40, a CD40 fusion protein, an anti-gp39, antibody or a fragment thereof that binds gp39.

14. The method of claim 13 wherein the gp39 antagonist is an anti-gp39 antibody or fragment thereof that binds gp39.

15. The method of claim 14 wherein the antibody is a humanized antibody.

16. The method of claim 14 wherein the antibody is a chimeric antibody.

17. The method of claim 13 wherein the gp39 antagonist is soluble CD40 or a CD40 fusion protein.

18. A method for treating oophoritis in a subject in need of such treatment comprising administering a therapeutically effective amount of a gp39 antagonist selected

F1

G

06/17/2002 HWARZ11 00000062 033975 09223634

01 FC:102 04.00 CH

2